Insuficiencia cardíaca crónica

IECA/ARA-II, beta- blockers and aldosterone antagonists are drugs that have been shown to improve survival in HF patients. Recently, a new compound (LCZ696) that combines an ARA-II (valsartan) and a neprilysin inhibitor (sacubitril) have proven better than an IECA (enalapril) in reducing the risk of death and hospitalisation due to HF.